Omada Health, Inc. (OMDA) Stock Price & Analysis
Omada Health, Inc. (OMDA) closed at USD 18.98 on Thursday, October 22, 2026, down 3.46% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 19.66; the Oct 22, 2026 session ranged USD 18.58–19.71 on volume of 686,526 shares. Market capitalization is $1.16B, with a 52-week range of USD 10.28–26.92 (NMS). Source: Nexqual, retrieved October 23, 2026 at 10:11 UTC.
Also available as compact Markdown for AI agents: nexqual.com/OMDA.md
Key facts (OMDA)
- Last four reported quarters (through Jun 30, 2026): revenue $310M, net income $4.3M (1.4% margin), free cash flow $22.7M (SEC filings).
- Valuation: P/E 269.9x.
- Analysts: Buy (mean 1.75 on a 1–5 scale) (12 analysts), mean target USD 28.42 (range 22–35).
- Total return with dividends: 1Y -26.1% vs S&P 500 +14.9%; 5Y -17.5% vs S&P 500 +80.3%.
- Next earnings: 2026-11-05, EPS estimate USD 0.1, revenue estimate $85.6M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (OMDA)
| USD | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|
| Revenue | $123M | $170M | $260M | $310M |
| Gross profit | $70.0M | $103M | $171M | — |
| Operating income | -$66.0M | -$43.7M | -$12.0M | -$464K |
| Net income | -$67.5M | -$47.1M | -$12.8M | $4.3M |
| EPS (diluted) | -$9.52 | -$6.11 | -$0.35 | — |
| Free cash flow | -$50.2M | -$34.8M | $16.9M | $22.7M |
| Gross margin | 57.0% | 60.6% | 65.7% | — |
| Operating margin | -53.8% | -25.7% | -4.6% | -0.1% |
| Net margin | -55.0% | -27.8% | -4.9% | 1.4% |
| Revenue growth | — | +38.3% | +53.2% | — |
| Cash + short-term investments | $116M | $76.4M | $222M | — |
| Total debt | — | $29.8M | $0K | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (OMDA)
P/E 269.9x · P/S 3.8x · P/FCF 51.1x · P/B 4.6x · FCF yield 1.96% · Earnings yield 0.37%
Analysts (OMDA)
Consensus Buy (mean 1.75 on a 1–5 scale), 12 analysts; mean target USD 28.42 (low 22, high 35).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-14 | Freedom Capital Markets | Maintained | Buy | $35 |
| 2026-09-14 | Freedom Capital Markets | Maintained | Buy | $35 |
| 2026-09-11 | Barclays | Target raised | Overweight | $25 → $27 |
| 2026-09-11 | Needham | Reiterated | Buy | $28 |
| 2026-09-11 | BTIG | Reiterated | Buy | $35 |
| 2026-08-14 | JP Morgan | Target raised | Overweight | $26 → $30 |
| 2026-08-14 | Citizens | Target raised | Market Outperform | $27 → $32 |
| 2026-08-12 | Baird | Target raised | Neutral | $15 → $25 |
| 2026-08-10 | BTIG | Target raised | Buy | $30 → $35 |
| 2026-08-03 | Barclays | Target raised | Overweight | $20 → $25 |
| 2026-07-21 | Canaccord Genuity | Target raised | Buy | $24 → $28 |
| 2026-07-20 | Citizens | Target raised | Market Outperform | $21 → $27 |
Total return (dividends reinvested) (OMDA)
| 1Y (from 2025-10-23) | 5Y (from 2025-06-02) | |
|---|---|---|
| Total return | -26.1% | -17.5% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | -26.2% | -12.9% |
| Volatility (annualized) | 63.3% | 69.0% |
| Max drawdown | -59.1% (Oct 2025→Feb 2026) | -56.3% (Oct 2025→Feb 2026) |
OMDA analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $0.10 | $0.09 | +9.9% | $85.6M | 5 |
| Next quarter (ends Dec 2026) | $0.11 | $0.13 | -13.1% | $87.0M | 5 |
| Current fiscal year (ends Dec 2026) | $0.44 | $0.33 | +33.5% | $338.7M | 5 |
| Next fiscal year (ends Dec 2027) | $0.56 | $0.48 | +16.7% | $407.8M | 5 |
Key Statistics (as of October 23, 2026 at 10:11 UTC)
| Price | USD 18.98 |
|---|---|
| Change | ▼ 3.46% (down) |
| Previous Close | USD 19.66 |
| Open | USD 19.31 |
| Day Range | USD 18.58 – 19.71 |
| 52-Week Range | USD 10.28 – 26.92 |
| Volume | 686,526 shares |
| Market Cap | $1.16B |
| Exchange | NMS |
Technical Analysis (OMDA)
Nexqual's technical model rates OMDA "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of October 23, 2026 at 10:11 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 42.5 (neutral) |
| vs SMA50 | Below (USD 21.34) |
| MACD | -0.62 (negative) |
Analyst Ratings (OMDA)
Wall Street analysts rate OMDA "Buy" based on 12 analysts, with a mean price target of USD 28.42 (range USD 22–35), per Nexqual as of October 23, 2026 at 10:11 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 12 |
| Mean Target | USD 28.42 |
| High Target | USD 35 |
| Low Target | USD 22 |
| Buy / Hold / Sell | 10 / 2 / 0 |
Earnings (OMDA)
| Next Earnings Date | 2026-11-05 |
|---|---|
| EPS Estimate | USD 0.1 |
| Revenue Estimate | $85.64M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 0.2 vs est 0.06 ▲ beat |
| 2026-03-31 | USD 0.05 vs est -0.04 ▲ beat |
| 2025-12-31 | USD 0.16 vs est 0.03 ▲ beat |
| 2025-09-30 | USD 0.03 vs est -0.07 ▲ beat |
Source: Nexqual, October 23, 2026 at 10:11 UTC.
Financials & Fundamentals (OMDA)
| Total Revenue | $309.76M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +43.10% |
| Gross Margin | +68.19% |
| Operating Margin | +4.04% |
| Profit Margin | +1.39% |
| ROE | +1.84% |
| Current Ratio | 3.91 |
| Total Cash | $221.71M |
| Total Debt | $0 |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | $22.73M (7.3% of revenue) |
Source: Nexqual, October 23, 2026 at 10:11 UTC.
Financial Health Score (OMDA)
Nexqual rates Omada Health, Inc.'s overall financial health "Solid" across five dimensions, as of October 23, 2026 at 10:11 UTC.
| Growth | Strong — Revenue +43% YoY (latest Q) |
|---|---|
| Profitability | Strong — Gross margin 68%, operating 4% (last 12 months) |
| Balance Sheet | Mixed — $222M cash and investments, no debt (Dec 2025, SEC) |
| Cash Flow | Solid — FCF $23M (last 4 quarters to Jun 2026, SEC), 7% margin |
| Efficiency | Weak — ROE 2%, ROA -0.1% |
Ownership (OMDA)
| Insider Ownership | +2.14% |
|---|---|
| Institutional Ownership | +88.18% |
| Shares Outstanding | 61.22M |
| Float | 51.03M |
| Short % of Float | +12.41% |
Source: Nexqual, October 23, 2026 at 10:11 UTC.
Leadership (OMDA)
Omada Health, Inc. is led by Sean P. Duffy, Co-Founder, CEO & Director, per Nexqual as of October 23, 2026 at 10:11 UTC.
| Co-Founder, CEO & Director | Sean P. Duffy |
|---|---|
| President | Wei-Li Shao |
| Chief Financial Officer | Steven L. Cook |
| Senior Vice President of Corporate Strategy & Operations | Lauren Fix |
| Chief Technology Officer | Sunil Kayiti |
Major Backers & Investors (OMDA)
Notable institutional backers of Omada Health, Inc. include Revelation Capital Management, LLC, Divisadero Street Capital Management, LP, American Century Companies Inc, according to Nexqual as of October 23, 2026 at 10:11 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Revelation Capital Management, LLC | 7.94% |
| Divisadero Street Capital Management, LP | 6.21% |
| American Century Companies Inc | 6.01% |
| Cigna Investments Inc/New | 5.63% |
| Morgan Stanley | 4.58% |
| FMR, LLC | 4.53% |
| NVP Associates, LLC | 4.13% |
| Millennium Management | 2.82% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 3.63% |
| Vanguard Group | 3.15% |
Source: Nexqual, October 23, 2026 at 10:11 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| TDOC | Teladoc Health, Inc. | USD 6.32 | ▲ 0.32% |
| GDRX | GoodRx Holdings, Inc. | USD 3.62 | ▲ 1.4% |
| HSTM | HealthStream, Inc. | USD 34.59 | ▲ 3.22% |
| CERT | Certara, Inc. | USD 10.09 | ▼ 0.88% |
| OMCL | Omnicell, Inc. | USD 37.1 | ▲ 2.09% |
| SDGR | Schrodinger, Inc. | USD 22.6 | ▼ 5.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 10:11 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt